Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Bob More
AddedMar 31, 2024
UpdatedJun 28, 2026
Bob More

Bob More

Board Member, Nuon Therapeutics

Crunchbase

Bob More's Career

Nuon Therapeutics
Nuon Therapeutics

San Mateo, CA, US

Board Member· Board
Carticept Medical
Carticept Medical

Alpharetta, GA, US

Board Member· Board
Moximed
Moximed

Hayward, CA, US

Board Member· Board
Esprit Pharma
Esprit Pharma

East Brunswick, NJ, US

Board Member· Board
Affinivax
Affinivax

Cambridge, MA, US

Board Member· Board
eGenesis
eGenesis

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Bob More's Career

Nuon Therapeutics
Nuon Therapeutics
Series A$48M752002San Mateo, CA, US
Board Member· Board

Leadership at Nuon Therapeutics

Joshua FunderJoshua FunderBoard Member
Lawrence SteinmanLawrence SteinmanFounder
Carticept Medical
Carticept Medical
Acquired$30M02005Alpharetta, GA, US
Board Member· Board

Leadership at Carticept Medical

Barbara D BoyanBarbara D BoyanBoard Member
Brian HalakBrian HalakBoard Member
Tim PatrickTim PatrickBoard Member
Ryan DrantRyan DrantBoard Member
Gilbert PriceGilbert PriceBoard Member
Moximed
Moximed
Public$183.2M452006Hayward, CA, US
Board Member· Board

Leadership at Moximed

Brigitte SmithBrigitte SmithBoard Member
Josh MakowerJosh MakowerBoard Member
Arthur FrankenArthur FrankenBoard Member
Anton CliffordAnton CliffordCo-Founder
Robert K Anderson \"Bob\"Robert K Anderson \"Bob\"Board Member
Kevin SidowKevin SidowCo-Founder & CEO
Esprit Pharma
Esprit Pharma
Acquired$269.5M02004East Brunswick, NJ, US
Board Member· Board

Leadership at Esprit Pharma

Joseph E SmithJoseph E SmithBoard Member

Similar to Esprit Pharma

Spes PharmaceuticalsSpes PharmaceuticalsNorth Brunswick, NJ, USPharmaceuticalsest. 2017Spes PharmaceuticalsNorth Brunswick, NJ, US · est. 2017

Spes Pharmaceuticals Inc., a specialty biotech firm, develops and manufactures drugs and agricultural products.

Pre-Seed · $2M8
Escient PharmaceuticalsEscient PharmaceuticalsSan Diego, CA, USDrugs, Pharmaceuticalsest. 2018Escient PharmaceuticalsSan Diego, CA, US · est. 2018

Escient Pharmaceuticals: A clinical-stage company developing drugs for serious, unserved medical needs.

Public · $237.5M56
Union Springs PharmaceuticalsUnion Springs PharmaceuticalsUnion Star, KY, USHealthcare Products, Pharmaceuticalsest. 2008Union Springs PharmaceuticalsUnion Star, KY, US · est. 2008

Union Springs Pharmaceuticals: A specialty OTC company developing and commercializing health care products in the US.

Series A · $5M200
Epirus BiopharmaceuticalsEpirus BiopharmaceuticalsBoston, MA, USPharmaceuticals, Therapeuticsest. 2000Epirus BiopharmaceuticalsBoston, MA, US · est. 2000

Boston-based EPIRUS Biopharmaceuticals develops novel treatments for hypothyroidism and immuno-inflammatory diseases globally.

Public · $83.1M73
Affinivax
Affinivax
Acquired$377.5M02014Cambridge, MA, US
Board Member· Board

Leadership at Affinivax

Steven M. AltschulerSteven M. AltschulerBoard Member
Kamran TavangarKamran TavangarCo-Founder
George SiberGeorge SiberBoard Member
Richard MalleyRichard MalleyBoard Member
Fran HellerFran HellerBoard Member
Steve BruggerSteve BruggerCEO
eGenesis
eGenesis
Series C$265M1052015Cambridge, MA, US
Board Member· Board

Leadership at eGenesis

Isaac CiechanoverIsaac CiechanoverBoard Member
Al WiegmanAl WiegmanBoard Member
Boris NikolicBoris NikolicBoard Member
Julie SunderlandJulie SunderlandBoard Member
Mike CurtisMike CurtisCEO
Daniel LynchDaniel LynchBoard Member

Similar to eGenesis

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
InGeneronInGeneronHouston, TX, USRegenerative Therapiesest. 2006InGeneronHouston, TX, US · est. 2006

InGeneron: A multinational biotech firm unlocking patient healing through innovative regenerative therapies.

Series D · $51M32
ExogenesisExogenesisBillerica, MA, USMedical Devicesest. 2005ExogenesisBillerica, MA, US · est. 2005

Exogenesis Corp., based in Billerica, US, develops and processes implantable medical devices.

Seed · $7.8M17
InscriptaInscriptaBoulder, CO, USGenome Engineeringest. 2015InscriptaBoulder, CO, US · est. 2015

Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.

Series A · $463.9M178

Bob More's Co-Investors

Darren LachtmanDarren LachtmanCo-invested · CollX SeedScott Keeney / DJ SkeeScott Keeney / DJ SkeeCo-invested · CollX SeedDavid AdelmanDavid AdelmanCo-invested · CollX SeedBrad StadlerBrad StadlerCo-invested · CollX SeedNat TurnerNat TurnerCo-invested · CollX SeedRyan SchinmanRyan SchinmanCo-invested · CollX SeedRyan SchinmanRyan SchinmanCo-invested · CollX SeedRogers HealyRogers HealyCo-invested · CollX Pre-Seed

Bob More's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Bob More

Bob RosenthalBob RosenthalBoard Member · Bruker BioSpinBob CarpenterBob CarpenterCo-Founder · GelTex PharmaceuticalsBradley BolzonBradley BolzonBoard Member · Tempest TherapeuticsMike RossMike RossBoard Member · Deciphera PharmaceuticalsBob BaumgartnerBob BaumgartnerBoard Member · Bio-TechneSimon MoroneySimon MoroneyBoard Member · Novartis